AD Patients for Alzheimer's Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer's DiseaseGammaSense Stimulation device - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of the study is to investigate the efficacy of cortical gamma oscillation on visual sensory processing and cognitive function in Alzheimer's Disease (AD) patients by combining a therapeutic sensory stimulation device capable of evoking 40-Hz gamma oscillation via non-invasive visual and auditory stimulation with pre-established markers of cortical network activity, i.e., electroencephalography (EEG) and event-related potentials (ERP), to evaluate the applicability of the 40-Hz multimodel sensory stimulation as a novel therapeutic approach for treatment of AD patients.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 8 weeks

8 weeks
Cognitive Status
Cortical Network Functioning
Resting state functional magnetic resonance imaging

Trial Safety

Trial Design

1 Treatment Group

AD Patients
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: AD Patients · No Placebo Group · N/A

AD Patients
Device
Experimental Group · 1 Intervention: GammaSense Stimulation device · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 8 weeks

Who is running the clinical trial?

University of Tennessee Medical CenterLead Sponsor
4 Previous Clinical Trials
237 Total Patients Enrolled
Roberto Fernandez-Romero, MDPrincipal InvestigatorUniversity of Tennessee Medical Center

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be fluent in English and literate in English.
You are able to consent for yourself based upon the MacArthur Competence Assessment Tool for Clinical Research.